These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Seroprevalence of rubella antibodies in The Netherlands after 32 years of high vaccination coverage.
    Author: Smits G, Mollema L, Hahné S, de Melker H, Tcherniaeva I, van der Klis F, Berbers G.
    Journal: Vaccine; 2014 Apr 01; 32(16):1890-5. PubMed ID: 24513012.
    Abstract:
    Here we present rubella virus specific antibody levels in a large cross-sectional population-based serosurveillance study performed in The Netherlands in 2006/2007. In the nationwide sample, seroprevalence was high (95%). Higher levels of rubella specific antibodies were observed in the naturally infected cohorts compared with the vaccinated cohorts. After both vaccinations, the geometric mean concentration of rubella specific antibodies remained well above the protective level. However, antibody concentrations decreased faster after one than after two vaccinations. Infants too young to be vaccinated were a risk group in the nationwide sample. In the orthodox protestant group, individuals younger than 6 years of age were at risk for an infection with rubella, consistent with a small local outbreak that recently occurred at an orthodox protestant primary school. The general Dutch population is well protected against an infection with rubella virus. However, monitoring the rubella specific seroprevalence remains an important surveillance tool to assess possible groups at risk.
    [Abstract] [Full Text] [Related] [New Search]